Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone416-679-0771
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.38 million
Profitability
Miscellaneous
Employees29
Next Earnings Date8/9/2019 (Estimated)
OptionableNot Optionable
Acerus Pharmaceuticals (OTCMKTS:ASPCF) Frequently Asked Questions
What is Acerus Pharmaceuticals' stock symbol?
Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."
How were Acerus Pharmaceuticals' earnings last quarter?
Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) issued its earnings results on Monday, May, 13th. The company reported ($0.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The business had revenue of $2.17 million for the quarter. Acerus Pharmaceuticals had a negative return on equity of 674.68% and a negative net margin of 236.97%. View Acerus Pharmaceuticals' Earnings History.
When is Acerus Pharmaceuticals' next earnings date?
Has Acerus Pharmaceuticals been receiving favorable news coverage?
News stories about ASPCF stock have trended very negative on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Acerus Pharmaceuticals.
Who are some of Acerus Pharmaceuticals' key competitors?
Some companies that are related to Acerus Pharmaceuticals include Entasis Therapeutics (ETTX), Otonomy (OTIC), Acasti Pharma (ACST), Merrimack Pharmaceuticals (MACK), VERONA PHARMA P/S (VRNA), Unum Therapeutics (UMRX), SCYNEXIS (SCYX), Relmada Therapeutics (RLMD), Ovid Therapeutics (OVID), Spring Bank Pharmaceuticals (SBPH), vTv Therapeutics (VTVT), Aravive (ARAV), Novan (NOVN), Alimera Sciences (ALIM) and Agile Therapeutics (AGRX).
Who are Acerus Pharmaceuticals' key executives?
Acerus Pharmaceuticals' management team includes the folowing people:
- Dr. Nathan Bryson, Chief Scientific Officer
- Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
- Mr. Edward Gudaitis, Pres , CEO & Director
- Mr. Robert M. Motz, Chief Financial Officer
- Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL
How do I buy shares of Acerus Pharmaceuticals?
Shares of ASPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acerus Pharmaceuticals' stock price today?
One share of ASPCF stock can currently be purchased for approximately $0.0783.
How big of a company is Acerus Pharmaceuticals?
What is Acerus Pharmaceuticals' official website?
How can I contact Acerus Pharmaceuticals?
Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The company can be reached via phone at 416-679-0771 or via email at [email protected]
MarketBeat Community Rating for Acerus Pharmaceuticals (OTCMKTS ASPCF)
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASPCF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASPCF will underperform the S&P 500 over the long term. You may vote once every thirty days.
